SPIRIT IV Trial Comparing Xience V To Taxus Leads TCT Stent News
Abbott's Xience V everolimus-eluting stent outperformed Boston Scientific's Taxus Express2 paclitaxel eluting stent in the 3,690-patient SPIRIT IV trial randomized trial, according to 12-month results released at the 2009 Transcatheter Cardiovascular Therapeutics conferenc